This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Emerson (EMR) Meets Q2 Earnings Estimates, Lowers FY19 View (Revised)
by Zacks Equity Research
Emerson's (EMR) second-quarter fiscal 2019 earnings meet estimates while increase year over year on sales growth and lower share count.
Emerson (EMR) Meets Q2 Earnings Estimates, Lowers FY19 View
by Zacks Equity Research
Emerson's (EMR) second-quarter fiscal 2019 earnings meet estimates while increase year over year on sales growth, margin improvement and lower share count.
Emerson Electric (EMR) Meets Q2 Earnings Estimates
by Zacks Equity Research
Emerson Electric (EMR) delivered earnings and revenue surprises of 0.00% and -1.74%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Emerson (EMR) to Report Q2 Earnings: Will it Disappoint?
by Zacks Equity Research
Emerson's (EMR) second-quarter fiscal 2019 results are likely to be hurt by rising operating costs and expenses, and unfavorable movement in foreign currencies.
Eaton (ETN) Q1 Earnings Beat Estimates, 2019 Guidance Up
by Zacks Equity Research
Eaton's (ETN) impressive Q1 earnings, which are driven by higher organic sales, allow the company to upwardly revise its 2019 guidance.
Emerson Electric (EMR) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Emerson Electric (EMR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Emerson (EMR) Buys Bio-G to Boost Biomanufacturing Efficiency
by Zacks Equity Research
Emerson's (EMR) life sciences technology expertise combined with Bio-G's modeling & scheduling software solutions will aid biomanufacturing companies to optimize the production of patient therapies.
Emerson Stands on Solid Footing Across Markets Amid Risks
by Zacks Equity Research
Strong Maintenance, Repair and Operations projects and ongoing small to mid-sized brownfield projects will drive Emerson's (EMR) growth. However, high cost of sales is a concern.
Will Cintas (CTAS) Maintain Beat Streak in Q3 Earnings?
by Zacks Equity Research
Strength in the Uniform Rental and Facility Services segment, accretive acquisitions and a solid product portfolio to drive Cintas' (CTAS) Q3 results.
Emerson's (EMR) DeltaV Automation System Gets Certification
by Zacks Equity Research
Emerson's (EMR) receipt of latest certification for its DeltaV distributed control and safety systems confirms its adherence to cybersecurity requirements for process and safety controls.
Emerson Chosen by IndianOil for Modernization of Refineries
by Zacks Equity Research
Emerson's (EMR) multiple contracts with IndianOil will help the latter to modernize its operations and emissions programs at refineries.
Why Is Emerson Electric (EMR) Up 1% Since Last Earnings Report?
by Zacks Equity Research
Emerson Electric (EMR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Emerson (EMR) Unveils New Service Center in Permian Basin
by Zacks Equity Research
Emerson's (EMR) newly opened service center will cater to the increasing need for digital technologies for optimization of production efficiencies.
Emerson & HID Global to Offer Healthcare Monitoring Solution
by Zacks Equity Research
Emerson (EMR) in partnership with HID Global will offer healthcare providers with an advanced medical-grade temperature monitoring solution.
Emerson to Gain From Solid Demand in Key Markets Amid Risks
by Zacks Equity Research
Strong Maintenance, Repair and Operations projects and ongoing small to mid-sized brownfield projects will boost Emerson's (EMR) growth. High cost of sales due to material cost inflation is a concern.
ENS or EMR: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ENS vs. EMR: Which Stock Is the Better Value Option?
Emerson (EMR) Q1 Earnings Beat, Revenues Miss Estimates
by Zacks Equity Research
Emerson (EMR) posts impressive first-quarter fiscal 2019 adjusted earnings, backed by favorable global market conditions.
Emerson Electric (EMR) Q1 Earnings Top Estimates
by Zacks Equity Research
Emerson Electric (EMR) delivered earnings and revenue surprises of 12.12% and -1.90%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
Emerson (EMR) to Report Q1 Earnings: Beat in the Cards?
by Zacks Equity Research
Emerson's (EMR) first-quarter fiscal 2019 earnings are likely to gain from strong prospects in the Automation Solutions and Commercial & Residential Solutions segments.
Eaton (ETN) Q4 Earnings Top Estimates on Higher Organic Sales
by Zacks Equity Research
Eaton's (ETN) fourth-quarter earnings and total revenues beat the Zacks Consensus Estimate, courtesy of strong organic sales from majority of its segments.
Honeywell (HON) to Post Q4 Earnings: Another Beat in Store?
by Zacks Equity Research
Honeywell's (HON) fourth-quarter earnings are likely to gain from strong prospects in the company's Aerospace and Performance Materials and Technologies segments.
Emerson Electric (EMR) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Emerson Electric (EMR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What's in Store for Fortune Brands (FBHS) in Q4 Earnings?
by Zacks Equity Research
Rising cost of sales and operating expenses, higher freight charges and inefficiencies within Fortune Brands Home & Security's (FBHS) Security operations will weigh over its fourth-quarter results.
Eaton (ETN) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Eaton (ETN) is likely to benefit from the improvement in end-market conditions when it reports fourth-quarter results on Jan 31, 2019.
Can Danaher (DHR) Maintain its Beat Streak in Q4 Earnings?
by Zacks Equity Research
Strength in Life Sciences business, accretive acquisitions and a solid product portfolio are conducive to Danaher's (DHR) likely encouraging Q4 results. However, high cost of sales remains a drag.